Description
While several COVID-19 Nanoparticle-based vaccines have been developed during the past year, prior to this pandemic only a small number of NVs have been approved for human use (hepatitis, influenza, human papilloma virus) and were limited to the use of liposomes or virus-like particles. This content is focused on two categories of COVID-19 nanovaccines, protein and nucleic acids-based, containing “synthetic” NPs in their formulation. The Table reports the list of COVID-19 Nanovaccines currently in clinical trials or already approved for humans use. The list is organized into five different groups according to the types of nanocarrier used: ionizable lipid nanoparticles, proteolipid vehicles, polymeric nanoparticles, nanoemulsions, or virus like particles.
Contact
Contributors
-
- Davide Magrì
-
- Luigi Calzolai
-
- Sabrina Gioria
How to cite
Magrì, Davide; Calzolai, Luigi; Gioria, Sabrina (2021): Nanoparticle-based vaccines in clinical trial/use for COVID-19 and licensed for other pathogens. European Commission, Joint Research Centre (JRC) [Dataset] PID: http://data.europa.eu/89h/1575f3b3-f8e6-4f6c-a296-77e8d1be4ee1
Data access
Additional information
- Published by
- European Commission, Joint Research Centre
- Created date
- 2021-04-06
- Modified date
- 2023-10-24
- Issued date
- 2021-04-01
- Data theme(s)
- Health
- Update frequency
- unknown
- Identifier
- http://data.europa.eu/89h/1575f3b3-f8e6-4f6c-a296-77e8d1be4ee1
- Popularity
-